UK cuts three months off drug reclassification process under "better regulation" initiative
This article was originally published in SRA
Improved procedures at the Medicines and Healthcare products Regulatory Agency in the UK should cut around three months off the time it takes the agency to process applications from drug companies to change the legal classification status of their medicines, for example from prescription-only to pharmacy or from pharmacy to general sales1.
You may also be interested in...
The UK’s deployment of COVID-19 vaccines has left vaccine manufacturers worried about emerging discussions on dosing strategies that may not be supported by authorized labeling or published clinical data.
Existing importers and manufacturers of certain medical devices can continue marketing their products for six months or until the Indian medtech regulator makes a final decision on their pending licensing applications.
Differences between how Australia and the EU define “central circulatory system” has resulted in different risk classification levels being assigned to some devices in the two jurisdictions.